Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$7.74 USD
-0.27 (-3.31%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $7.75 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Mind Medicine (MindMed) Inc. [MNMD]
Reports for Purchase
Showing records 41 - 60 ( 73 total )
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage, Establishing Buy Rating and $25 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Well Capitalized Beyond Phase 2 Proof of Concept Data For LSD in Anxiety and ADHD Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
HCW "At Home" Recap: Reiterate Buy Ahead of Start of Phase 2b Program Evalauting LSD in Anxiety
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Adjusting Price Target, Due to Offering of Shares
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
JAMA Publication Further Supports Psychedelic Approach to Treat Alcoholism, a Potential $20B-Plus Global Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Compelling LSD Publication; MDMA Study Starts; Reverse Split Complete; Adjusting Price Target to $75 and Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Adjusting Price Target, Reflecting Reverse Share Split
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Valuation of Leader in Emerging $400B Mental Healthcare Market Remains Attractive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Change Your Mind: Outlining Mental Healthcare Treatments of the Future With $400B Annual Revenue Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Potential Blockbuster LSD Program Progressing; 18-MC Addiction Program to Be Partnered; Lowering Price Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Zolunicant Clears First Hurdle With Potential to Tame America''s Addiction Crisis; Broad Pipeline Advancing; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P